Jake G Natalini1,2, Joshua F Baker2,3,4, Namrata Singh5, Tina D Mahajan6, Punyasha Roul6, Geoffrey M Thiele6,7, Brian C Sauer8,9, Cheilonda R Johnson1, Steven M Kawut1,2, Ted R Mikuls6,7, Bryant R England6,7. 1. Division of Pulmonary, Allergy, and Critical Care, Department of Medicine. 2. Center for Clinical Epidemiology and Biostatistics, and. 3. Division of Rheumatology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 4. Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania. 5. Division of Rheumatology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington. 6. Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska. 7. VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska. 8. Division of Biostatistics, University of Utah School of Medicine, Salt Lake City, Utah; and. 9. VA Salt Lake City Health Care System, Salt Lake City, Utah.
Abstract
Rationale: Prior studies investigating associations of rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) seropositivity with risk for rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) have mostly used cross-sectional or case-control designs. Objectives: To determine whether combined autoantibody seropositivity and higher individual autoantibody concentrations were associated with increased risk for RA-ILD in a prospective RA cohort. Methods: Within the Veterans Affairs Rheumatoid Arthritis prospective registry, we performed a cross-sectional study of prevalent ILD and a retrospective cohort study of incident ILD (diagnosed after at least 12 mo of longitudinal follow-up). We used logistic and Cox regression methods to determine whether combined RF/ACPA seropositivity and higher autoantibody concentrations were independently associated with greater risk for prevalent and incident ILD, respectively. Results: Among 2,328 participants (median age 64 yr, 89.3% male), 100 (4.3%) subjects had prevalent ILD at enrollment. During 14,281 patient-years of follow-up, 83 (3.7%) of the remaining 2,228 were subsequently diagnosed with incident ILD (5.8 cases per 1,000 person-years). Patients with combined RF/ACPA seropositivity had a higher probability of prevalent ILD compared with seronegative subjects (odds ratio [OR], 2.90; 95% confidence interval [CI], 1.24-6.78). RF titers demonstrated a monotonic association with prevalent ILD (OR, 2.69; 95% CI, 1.11-6.51 for low-positive [15-45 IU/ml] titers; OR, 3.40; 95% CI, 1.61-7.18 for high-positive [>45 IU/ml] titers; P for trend 0.01). Patients with high-positive (>15 U/ml) ACPA titers were also at higher risk for prevalent ILD (OR, 1.91; 95% CI, 1.04-3.49) compared with ACPA-negative subjects. Combined RF/ACPA seropositivity was not associated with increased risk for incident ILD, nor were high- or low-positive RF or ACPA titers. In a piecewise linear spline model, however, RF titers greater than 90 IU/ml independently correlated with increased risk for incident ILD (hazard ratio, 1.68, 95% CI, 1.02-2.77).Conclusions: Combined RF/ACPA seropositivity and individual autoantibody concentrations were strongly associated with prevalent but not incident RA-ILD. Only patients with RF concentrations >90 IU/ml were observed to be at higher risk of incident RA-ILD.
Rationale: Prior studies investigating associations of rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) seropositivity with risk for rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) have mostly used cross-sectional or case-control designs. Objectives: To determine whether combined autoantibody seropositivity and higher individual autoantibody concentrations were associated with increased risk for RA-ILD in a prospective RA cohort. Methods: Within the Veterans Affairs Rheumatoid Arthritis prospective registry, we performed a cross-sectional study of prevalent ILD and a retrospective cohort study of incident ILD (diagnosed after at least 12 mo of longitudinal follow-up). We used logistic and Cox regression methods to determine whether combined RF/ACPA seropositivity and higher autoantibody concentrations were independently associated with greater risk for prevalent and incident ILD, respectively. Results: Among 2,328 participants (median age 64 yr, 89.3% male), 100 (4.3%) subjects had prevalent ILD at enrollment. During 14,281 patient-years of follow-up, 83 (3.7%) of the remaining 2,228 were subsequently diagnosed with incident ILD (5.8 cases per 1,000 person-years). Patients with combined RF/ACPA seropositivity had a higher probability of prevalent ILD compared with seronegative subjects (odds ratio [OR], 2.90; 95% confidence interval [CI], 1.24-6.78). RF titers demonstrated a monotonic association with prevalent ILD (OR, 2.69; 95% CI, 1.11-6.51 for low-positive [15-45 IU/ml] titers; OR, 3.40; 95% CI, 1.61-7.18 for high-positive [>45 IU/ml] titers; P for trend 0.01). Patients with high-positive (>15 U/ml) ACPA titers were also at higher risk for prevalent ILD (OR, 1.91; 95% CI, 1.04-3.49) compared with ACPA-negative subjects. Combined RF/ACPA seropositivity was not associated with increased risk for incident ILD, nor were high- or low-positive RF or ACPA titers. In a piecewise linear spline model, however, RF titers greater than 90 IU/ml independently correlated with increased risk for incident ILD (hazard ratio, 1.68, 95% CI, 1.02-2.77).Conclusions: Combined RF/ACPA seropositivity and individual autoantibody concentrations were strongly associated with prevalent but not incident RA-ILD. Only patients with RF concentrations >90 IU/ml were observed to be at higher risk of incident RA-ILD.
Authors: Bryant R England; Punyasha Roul; Tina D Mahajan; Namrata Singh; Fang Yu; Harlan Sayles; Grant W Cannon; Brian C Sauer; Joshua F Baker; Jeffrey R Curtis; Ted R Mikuls Journal: Arthritis Care Res (Hoboken) Date: 2020-10 Impact factor: 4.794
Authors: Gudrun Reynisdottir; Reza Karimi; Vijay Joshua; Helga Olsen; Aase Haj Hensvold; Anders Harju; Marianne Engström; Johan Grunewald; Sven Nyren; Anders Eklund; Lars Klareskog; Carl Magnus Sköld; Anca Irinel Catrina Journal: Arthritis Rheumatol Date: 2014-01 Impact factor: 10.995
Authors: F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra Journal: Arthritis Rheum Date: 1988-03
Authors: Ted R Mikuls; Rohit Gaurav; Geoffrey M Thiele; Bryant R England; Madison G Wolfe; Brianna P Shaw; Kristina L Bailey; Todd A Wyatt; Amy J Nelson; Michael J Duryee; Carlos D Hunter; Dong Wang; Debra J Romberger; Dana P Ascherman; Jill A Poole Journal: Int Immunopharmacol Date: 2021-08-27 Impact factor: 4.932
Authors: Bilal F Samhouri; Robert Vassallo; Sara J Achenbach; Vanessa L Kronzer; John M Davis; Elena Myasoedova; Cynthia S Crowson Journal: Arthritis Care Res (Hoboken) Date: 2022-01-07 Impact factor: 5.178
Authors: Jill A Poole; Ted R Mikuls; Geoffrey M Thiele; Rohit Gaurav; Amy J Nelson; Michael J Duryee; Ananya Mitra; Carlos Hunter; Todd A Wyatt; Bryant R England; Dana P Ascherman Journal: Respir Res Date: 2022-06-18